ProPhase is a development-stage company focused on genomics and diagnostic testing. Following the shutdown of its COVID-19 testing operations, the company’s primary operating business is Nebula Genomics. Nebula sells whole genome sequencing kits and subscriptions directly to consumers, providing health and ancestry reports based on a customer's full genetic data. ProPhase is also developing BE-Smart, a pre-commercialization diagnostic test for esophageal cancer risk. Developed in collaboration with Mayo Clinic, this test uses mass spectrometry and AI to analyze protein biomarkers in tissue samples. ProPhase intends to commercialize BE-Smart as a laboratory-developed test by billing insurance companies directly. A major part of the company's current activity involves pursuing unpaid COVID-19 testing receivables through Crown Medical to recover funds from insurance providers. ProPhase plans to use these collections to retire debt and fund future operations. The company’s strategy includes commercializing its cancer diagnostic through partner distribution networks and exploring a potential sale of its genomics unit. ProPhase also maintains minor interests in dietary supplements and preclinical oncology drug candidates.